Hims & Hers Health, Inc. Class A Common Stock (HIMS)
43.96
-20.26 (-31.55%)
NYSE · Last Trade: Jun 23rd, 2:59 PM EDT
Detailed Quote
Previous Close
64.22
Open
48.16
Bid
43.95
Ask
43.97
Day's Range
42.14 - 48.35
52 Week Range
13.47 - 72.98
Volume
142,244,529
Market Cap
-
PE Ratio (TTM)
-
EPS (TTM)
-
Dividend & Yield
N/A (N/A)
1 Month Average Volume
38,692,534
Chart
About Hims & Hers Health, Inc. Class A Common Stock (HIMS)
Hims & Hers Health Inc is a telehealth company that focuses on providing accessible and affordable healthcare solutions for a variety of needs, particularly focusing on personal wellness and self-care. The company offers a range of products and services, including prescription medications for conditions such as hair loss, erectile dysfunction, and skincare, as well as wellness supplements and telemedicine consultations. By leveraging technology, Hims & Hers aims to simplify the healthcare experience, making it more convenient for consumers to receive treatment and advice from licensed professionals without the barriers typically associated with traditional healthcare delivery. Read More
The Law Offices of Frank R. Cruz announces an investigation of Hims & Hers Health, Inc. (“Hims” or the “Company”) (NYSE: HIMS) on behalf of investors concerning the Company’s possible violations of federal securities laws.
Wall Street resilient as Iran fires missiles at U.S. bases in Qatar and Iraq, defying expectations in energy market. U.S. equities and gold up, bonds down.
The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) is currently investigating potential violations of the federal securities laws on behalf of investors of Hims & Hers Health, Inc. (NYSE: HIMS) (“Hims & Hers”).
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Hims & Hers Health, Inc. (“Hims & Hers” or the “Company”) (NYSE: HIMS).
Stay up-to-date with the latest market trends in the middle of the day on Monday. Explore the top gainers and losers during today's session in our detailed report.
Shares of telehealth company Hims & Hers Health (NYSE:HIMS) fell 29.2% in the morning session after Novo Nordisk, the maker of the weight loss drug Wegovy, announced it would terminate its agreement with the company (Hims & Hers).
Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Hims & Hers Health, Inc. (NYSE: HIMS) resulting from allegations that Hims & Hers may have issued materially misleading business information to the investing public.
Novo said that Hims & Hers failed to adhere to the law, which prohibits mass sales of compounded drugs. It alleged that the telehealth operator is promoting and selling illegitimate, knockoff versions of Wegovy.
A company with profits isn’t always a great investment.
Some struggle to maintain growth, face looming threats, or fail to reinvest wisely, limiting their future potential.
Mid-cap stocks often strike the right balance between having proven business models and market opportunities that can support $100 billion corporations.
However, they face intense competition from scaled industry giants and can be disrupted by new innovative players vying for a slice of the pie.
A number of stocks jumped in the afternoon session after the major indices rebounded (Nasdaq +1.5%, S&P 500 +1.0%) as reports pointed to easing tensions between Israel and Iran.
